We Offer Worldwide Shipping
Login Wishlist

Psoralen

$43

  • Brand : BIOFRON

  • Catalogue Number : BF-P3004

  • Specification : 98%

  • CAS number : 66-97-7

  • Formula : C11H6O3

  • Molecular Weight : 186.16

  • PUBCHEM ID : 6199

  • Volume : 25mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-P3004

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

186.16

Appearance

White crystalline powder

Botanical Source

Angelica decursiva,Callerya speciosa,Cullen corylifolium,Glehnia littoralis,Angelica biserrata

Structure Type

Phenylpropanoids

Category

Standards;Natural Pytochemical;API

SMILES

C1=CC(=O)OC2=CC3=C(C=CO3)C=C21

Synonyms

Furocoumarin/7H-Furo[3,2-g]chromen-7-one/Psoralen/Psoralene/prosuler/6,7-Furanocoumarin/Psorline-P/FICUSIN/7H-Furo[3,2-g][1]benzopyran-7-one

IUPAC Name

furo[3,2-g]chromen-7-one

Density

1.4±0.1 g/cm3

Solubility

Methanol; Acetontrile; Ethyl Acetate; DMSO

Flash Point

173.1±23.7 °C

Boiling Point

362.6±27.0 °C at 760 mmHg

Melting Point

160-162 °C

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2932200000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:66-97-7) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

31277690

Abstract

BACKGROUND:
Psoralen is a coumarin-like and coumarin-related benzofuran glycoside, which is a commonly used traditional Chinese medicine to treat patients with kidney and spleen-yang deficiency symptom. Psoralen has been reported to show estrogen-like activity, antioxidant activity, osteoblastic proliferation accelerating activity, antitumor effects and antibacterial activity. However, the antitumor mechanism of psoralen is not fully understood. This study aimed to investigate the therapeutic efficacy of psoralen in human hepatoma cell line SMMC7721 and the mechanism of antitumor effects.

RESULTS:
Psoralen inhibited proliferation of SMMC7721 in a dose- and time-dependent manner, and promoted apoptosis. Further, psoralen activated the ER stress signal pathway, including the expansion of endoplasmic reticulum, increasing the mRNA levels of GRP78, DDIT3, ATF4, XBP1, GADD34 and the protein levels of GDF15, GRP78, IRE1α, XBP-1s in a time-dependent manner. Psoralen induces cell cycle arrest at G1 phase by enhancing CyclinD1 and reducing CyclinE1 expression. Moreover, TUDC couldn’t inhibit the psoralen-induced ER stress in SMMC7721 cells.

CONCLUSIONS:
Psoralen can inhibit the proliferation of SMMC7721 cells and induce ER stress response to induce cell apoptosis, suggesting that psoralen may represent a novel therapeutic option for the prevention and treatment hepatocellular carcinoma.

KEYWORDS

Apoptosis; Endoplasmic reticulum stress; Hepatocellular carcinoma; Psoralen; SMMC7721 cell

Title

Psoralen inhibits malignant proliferation and induces apoptosis through triggering endoplasmic reticulum stress in human SMMC7721 hepatoma cells.

Author

Wang X1, Peng P1, Pan Z2, Fang Z1, Lu W1, Liu X1.

Publish date

2019 Jul 5

PMID

27777066

Abstract

Psoralen in combination with ultraviolet A radiation (PUVA) is an FDA recommended therapy for clinical application in the management of severe recalcitrant psoriasis. Psoralen acts by intercalation of DNA and upon exposure to UV-A, it forms monoadducts which in turn induce apoptosis. Poor skin deposition, weak percutaneous permeability of psoralen and adverse effects of severe burning, blisters, pigmentation associated with conventional topical psoralen vehicles hinders the therapeutic efficacy and safety of topical PUVA. The aim of the present study is to formulate psoralen loaded liposomal nanocarriers for enhanced skin penetration, safety and efficacy of topical PUVA in psoriasis. Two different liposomal compositions i.e., cationic liposomes composed of DC-Chol, cholesterol and anionic liposomes composed of egg lecithin, cholesterol, tetramyristoyl cardiolipin were prepared for the topical delivery of psoralen. Liposomal carriers were characterized with respect to size, zeta potential, entrapment efficiency, stability, in vitro drug release and in vivo studies. Both liposomes were prepared with particle size of nearly 100nm. Zeta potential and entrapment efficiency of cationic liposomes were +25.8mV, 75.12% and anionic liposomes were -28.5mV, 60.08% respectively. Liposomal dermal distribution demonstrated higher penetration of both liposomal carriers over solution. Similarly, skin permeation study indicated 5 fold increase in permeation of psoralen with liposomal carriers. Topical application of psoralen liposomal gels on imiquimod induced psoriatic plaque model reduced the symptoms of psoriasis and levels of key psoriatic cytokines such as tumor necrosis factor-α, IL-17 and IL-22. In conclusion, the developed liposomal carriers of psoralen were found to be promising and can find application for optimal safety and efficacy of topical PUVA in psoriasis.

Copyright © 2016 Elsevier B.V. All rights reserved.

KEYWORDS

Imiquimod induced psoriatic plaque model; Liposomes; Psoralen; Psoriasis; Skin penetration; Topical PUVA

Title

Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis.

Author

Doppalapudi S1, Jain A1, Chopra DK2, Khan W3.

Publish date

2017 Jan 1

PMID

32274473

Abstract

PURPOSE:
This study was designed to investigate the effect of psoralen on periodontal tissue reconstruction after orthodontic tooth movement(OTM) in rats.

METHODS:
Thirty-six male 6-week-old Wistar rats were randomly divided into 2 groups: the experimental group and the control group. The experimental group and the control group were all installed between the central incisor and the left maxillary first molars to pull the first molars away from the force device; after 21 days, the force was removed and the rats in 2 groups were given drug gavage. Rats in the experimental group were given a gavage of psoralen 8 mg/kg per day, while rats in the control group were given the same amount of 0.9% sodium chloride everyday. Maxillary casts were made every week during the experimental and were scanned by 3D Scanner to measure relapse distance, and histologic examination was conducted. After 28 days, the rats were sacrificed and rats’ upper jaw was separated. The remaining sections were immunohistochemically stained with BMP2 and BMP4. SPSS 19.0 software package was used for statistical analysis. RESULTS:Both groups had relapse after the force device was removed. Significant decrease of relapse percentage was observed in the experimental group compared with the control group at day 7,day 14,day 21 and day 28(P<0.05). The speed of relapse of both groups were fastest in the first week and slowed down in the second, third and fourth week gradually. The speed of relapse in the experimental group in the first week was significantly less than in the control group(P<0.05).The expression of BMP2 and BMP4 within periodontal membrane and alveolar bone was significantly higher in the experimental group than in the control group(P<0.05).

CONCLUSIONS:
Psoralen can accelerate the reconstruction of periodontal tissues of orthodontic tooth and reduce relapse.

Title

[Effect of psoralen on the stability after orthodontic tooth movement in rats].

Author

Liu XC1, Wang XX, Wu XX, Yan ZY, Zhang J.

Publish date

2019 Oct


Description :

Psoralen(Furocoumarin) is an active ingredient from Fructus Psoraleae; has anticancer activity.IC50 value:Target:in vitro: Psoralen dosages of 1-10 μM exhibited low cytotoxicity toward chondrocytes. However, a dosage of 100 μM suppressed the proliferation of chondrocytes. Different concentrations of psoralen treatments on chondrocytes revealed that GAG and Type II collagen synthesis increased, especially at 100 μM, by 0.39-fold and 0.48-fold, respectively, on day 3, and by 0.51-fold and 0.56-fold, respectively, on day 9 [1]. in vivo: Tumor volume inhibition rates were 43.75% and 40.18%, respectively, in the psoralen and isopsoralen low-dose groups, and tumor weight inhibition rates were 38.83% and 37.77%. Tumor volume inhibition rates were 67.86% and 66.96%, respectively, in the psoralen and isopsoralen high-dose groups, and tumor weight inhibition rates were 49.47% and 47.87% [2]. psoralen can inhibit metastasis of breast cancer to bone in vivo. Histological, molecular biological, and imaging analyses revealed that psoralen inhibits bone metastases in mice [3].